Estudo randomizado | Elacestrante (degradador oral do receptor seletivo de estrogênio) vs. terapia endócrina padrão para câncer de mama avançado positivo para receptor de estrogênio e negativo para receptor 2 do fator de crescimento epidérmico humano.

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial – Journal of Clinical Oncology

Comentário: EMERALD Trial: Oral Selective Estrogen Receptor Degrader as Second- or Third-Line Therapy for Advanced Breast Cancer – The ASCO Post